Hikma Pharmaceuticals PLC (LON:HIK) Insider Acquires £3,512,000 in Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Mazen Darwazah acquired 200,000 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Thursday, August 7th. The stock was acquired at an average cost of GBX 1,756 ($23.61) per share, for a total transaction of £3,512,000 ($4,721,699.38).

Hikma Pharmaceuticals Price Performance

Hikma Pharmaceuticals stock opened at GBX 1,729.97 ($23.26) on Monday. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The company has a market capitalization of £4.80 billion, a PE ratio of 16.98, a P/E/G ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals PLC has a 12 month low of GBX 1,690 ($22.72) and a 12 month high of GBX 2,360 ($31.73). The stock has a 50-day moving average price of GBX 2,010.20 and a two-hundred day moving average price of GBX 2,048.98.

Wall Street Analyst Weigh In

HIK has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Hikma Pharmaceuticals from GBX 2,600 ($34.96) to GBX 2,500 ($33.61) and set an “overweight” rating on the stock in a research note on Friday. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,600 ($34.96) target price on shares of Hikma Pharmaceuticals in a research report on Thursday.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.